Cardiol Therapeutics Inc. filings document the formal disclosures of a Canadian life sciences issuer listed on Nasdaq and the TSX. Recent Form 6-K reports furnish press releases and exhibits covering CardiolRx clinical programs, including MAVERIC in recurrent pericarditis and ARCHER in acute myocarditis, as well as CRD-38 development, patent updates, and operating results summarized with audited financial statements and management discussion.
The filing record also documents governance and capital-structure matters, including annual general meeting notices, Class A common share voting mechanics, bought deal private placement terms, underwriting agreements, and warrant indenture provisions. These filings describe the company’s securities, financing arrangements, clinical-development disclosures, and foreign-issuer reporting framework.
Cardiol Therapeutics Inc. entered into an underwriting agreement for a bought-deal private placement of 11,423,078 units at $1.30 per unit, for aggregate gross proceeds of $14,850,001.40. Each unit consists of one common share and one-half common share purchase warrant.
Each whole warrant allows the holder to buy one additional common share at $1.75 until January 23, 2028, potentially adding future equity if exercised. Canaccord Genuity Corp. acts as sole underwriter and bookrunner and will receive a cash commission equal to 6% of gross proceeds, plus reimbursed expenses, under Canadian listed issuer financing and other prospectus exemptions.
MMCAP International Inc. SPC and Asset Management Inc. have disclosed a significant passive stake in Cardiol Therapeutics Inc. They report beneficial ownership of 17,451,746 Class A Common Shares, representing 14.9% of the class as of January 23, 2026.
This position includes 11,740,207 Class A Common Shares and 5,711,539 additional Class A Common Shares underlying warrants exercisable within 60 days. The shares are held through a private investment fund managed by Asset Management Inc., and both parties state the holdings are not for the purpose of influencing control of Cardiol Therapeutics.
Cardiol Therapeutics Inc. entered into a bought deal private placement with Canaccord Genuity Corp., which agreed to purchase for resale 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million. The company granted the underwriter an option to buy up to an additional 1,038,462 units at the same price to raise up to a further $1,350,000 in gross proceeds.
Each unit consists of one common share and one-half of one warrant, with each whole warrant exercisable at $1.75 per share for 24 months from issuance. Cardiol plans to use the net proceeds to advance its research and clinical development programs, and for general and administrative expenses, working capital, and other expenses. Closing is targeted on or about January 23, 2026, subject to approvals, including TSX approval and execution of an underwriting agreement.
Cardiol Therapeutics Inc. has closed a previously announced bought-deal private placement of units, raising gross proceeds of $14.85 million. The company issued 11,423,078 units at $1.30 per unit, with each unit consisting of one Class A common share and one-half of a common share purchase warrant. Each whole warrant allows the holder to buy one additional share at an exercise price of $1.75 for 24 months from issuance. Cardiol paid the underwriter, Canaccord Genuity Corp., a cash commission equal to 6% of the gross proceeds. The company plans to use the net proceeds to advance its research and clinical development programs, and to fund general and administrative expenses, working capital, and other corporate needs.
Cardiol Therapeutics Inc. entered into a bought deal private placement, with a sole underwriter agreeing to purchase for resale 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million. The company also granted the underwriter a 10% option for up to 1,038,462 additional units at the same price to cover over-allotments.
Each unit includes one common share and one-half warrant, with each whole warrant exercisable at $1.75 per share for 24 months from issuance. Cardiol plans to use the net proceeds to advance its research and clinical development programs, and for general and administrative expenses, working capital, and other expenses.
The offering is expected to close on or about January 23, 2026, subject to conditions including TSX approval and completion of an underwriting agreement, and will be conducted under Canadian prospectus exemptions, including the Listed Issuer Financing Exemption.
Cardiol Therapeutics reports that its pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis has surpassed 50% patient enrollment, marking a key execution and risk‑reduction milestone for its lead registrational program. More than 15 leading cardiovascular centers in the United States are actively enrolling patients, with additional top-tier sites in Europe and Canada being activated, and the company expects full enrollment to be completed in Q2 2026.
MAVERIC is designed to enroll approximately 110 patients across about 25 centers in North America and Europe, with a primary endpoint of freedom from a new recurrent pericarditis episode after six months of double-blind treatment. The trial builds on positive Phase II MAvERIC-Pilot data showing rapid and sustained reductions in pain, inflammation, and recurrence rates, and on Phase II ARCHER data in myocarditis. Cardiol also highlights Orphan Drug Designation for CardiolRx™ in pericarditis and ongoing development of CRD-38 for inflammatory heart disease, including heart failure.
Cardiol Therapeutics (CRDL) furnished a Form 6-K that includes a news release stating it received a U.S. patent allowance broadly protecting its heart drugs to late 2040. The exhibit is a news release dated November 13, 2025.
The company indicates it files annual reports under cover of Form 40-F as a foreign private issuer.
Cardiol Therapeutics Inc. filed a Form F-10 base shelf registration to offer up to US $150,000,000 of securities under the MJDS. The shelf covers Common Shares, Debt Securities, Warrants, Subscription Receipts, and Units, to be sold from time to time during the 25-month period the prospectus remains effective, with specific terms to be set in prospectus supplements.
Amendment No. 1 adds that one or more selling securityholders may conduct secondary offerings by prospectus supplement, and the aggregate amount available for the company’s sales will be reduced by the aggregate amount of such secondary offerings. Cardiol’s Common Shares trade on the TSX and Nasdaq under “CRDL”.
Cardiol Therapeutics Inc. filed a Form 6-K as a foreign private issuer that reports under Form 40-F. The filing mainly furnishes a news release dated November 5, 2025, announcing that results from its Phase II ARCHER clinical trial will be presented at the European Society of Cardiology’s Scientific Meeting on Myocardial & Pericardial Diseases.